Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented

Abstract Objective: To determine the frequency of different outcomes in women participating in cervical screening. Design: Analysis of screening records from 348 419 women, and modelling of cases of cervical cancer and deaths with and without screening. Setting: Cervical screening programme in Bristol. Results: For every 10 000 women screened from 1976 to 1996, 1564 had abnormal cytology, 818 were investigated, and 543 had abnormal histology. One hundred and seventy six had persistent abnormality for two years or more. In the absence of screening 80 women would be expected to develop cancer of the cervix by 2011, of whom 25 would die. With screening 10 of these deaths would be avoided. Comparison of cumulative abnormality rates with numbers expected to develop cancer in the absence of screening suggests that at least 80% of high grade dyskaryosis and of high grade dysplasia would not progress to cancer. The lifetime risk of having abnormal cytology detected could be as high as 40% for women born since 1960. Conclusions: Screening is labour and resource intensive. It involves treatment for many women not destined to develop invasive cancer. The increased intervention rate for cervical abnormality in England is due to change in practice, not a cohort effect, and is probably the reason for the marked fall in incidence and mortality during the 1990s. For other cancers there is scope for major iatrogenic harm from screening because of invasive tests and treatments. What is already known on this topic Since the mid-1980s incidence of and mortality from cervical cancer in women born since the 1930s in England and Wales has fallen; screening is the most likely explanation For each death prevented many women have to be screened and many are treated who would not have developed a problem What this study adds In the NHS cervical screening programme around 1000 women need to be screened for 35 years to prevent one death Over 80% of women with high grade cervical intraepithelial neoplasia will not develop invasive cancer, but all need to be treated For each death prevented, over 150 women have an abnormal result, over 80 are referred for investigation, and over 50 have treatment Before the 1988 relaunch of screening with strict quality standards, for each death prevented there were 57 000 tests and 1955 women had abnormal results

[1]  London,et al.  General Medical Council , 1920 .

[2]  D. Evans,et al.  Terminology in gynaecological cytopathology: report of the Working Party of The British Society for Clinical Cytology , 1986, Journal of clinical pathology.

[3]  P. Walker,et al.  Anxieties in women undergoing colposcopy , 1990, British journal of obstetrics and gynaecology.

[4]  A. Ostör Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[5]  A. E. Raffle,et al.  Detection rates for abnormal cervical smears: what are we screening for? , 1995, The Lancet.

[6]  J. Habbema,et al.  Non-progression of cervical intraepithelial neoplasia estimated from population-screening data. , 1997, British Journal of Cancer.

[7]  J. Simpson,et al.  Progression and Regression of Low‐grade Epithelial Abnormalities of the Cervix , 1997, The Australian & New Zealand journal of obstetrics & gynaecology.

[8]  The cervical screening muddle , 1998 .

[9]  W. Frable,et al.  Medicolegal affairs. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. , 1998, Acta cytologica.

[10]  P. Foster,et al.  Reaching targets in the national cervical screening programme: are current practices unethical? , 1998, Journal of medical ethics.

[11]  The cervical screening muddle , 1998, The Lancet.

[12]  M Quinn,et al.  Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. , 1999, BMJ.

[13]  A. Miller,et al.  Natural history of dysplasia of the uterine cervix. , 1999, Journal of the National Cancer Institute.

[14]  J. Nottingham,et al.  Invited reviewBridging the knowledge gap and communicating uncertainties for informed consent in cervical cytology screening; we need unbiased information and a culture change , 1999, Cytopathology : official journal of the British Society for Clinical Cytology.

[15]  A. Raffle How long will screening myths survive? , 1999, The Lancet.

[16]  P. Sasieni,et al.  Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model , 1999, BMJ.

[17]  D. Slater Are women sufficiently well informed to provide valid consent for the cervical smear test? , 2000, Cytopathology : official journal of the British Society for Clinical Cytology.

[18]  H O Dickinson,et al.  Cancer trends in England and Wales , 2000, BMJ : British Medical Journal.

[19]  J. Dillner,et al.  Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  A. Raffle,et al.  Information about screening – is it to achieve high uptake or to ensure informed choice? , 2001, Health expectations : an international journal of public participation in health care and health policy.